The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hlL-4R). The formulations may contain, in addition to an anti-hlL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Formulación farmacéutica líquida estable que comprende un anticuerpo anti-receptor de interleuquina-4 alfa (IL-4R?), tampón acetato-histidina a un pH entre 5,6 a 6,2, polisorbato 20 u 80, sacarosa y arginina
